Biosimilars' growing popularity is predicted to provide attractive growth possibilities for global biotechnology companies. The launch of new biosimilars, for example, is estimated to save US$ 250 billion in healthcare costs between 2016 and 2025, according to the Association for Accessible Medicines.
Furthermore, customised medicine R&D is likely to contribute growth in Biotechnology. In January 2020, for example, researchers at the Biomedical Research Institute of MEDIPOST Co., Ltd. in South Korea published an analysis of the effects of spheroid umbilical cord blood-derived mesenchymal stem cells (MSCs) and proposed a new therapeutic approach, 3D spheroid formation of MSCs, to improve the regeneration process in osteoarthritis.
Discover the Complete Blog- https://bit.ly/3wa7XZM